Novacyt S.A.
(“Novacyt” or the “Company”)
Director/PCA Dealing
Paris, France and Camberley, UK – 18 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 18 March 2022 that Jean-Pierre Crinelli, a Non-Executive Director of Novacyt, acquired 3,208 ordinary shares in the Company at a price of €2.41 per share. Following the transaction, Mr Crinelli is interested in 33,981 ordinary shares representing 0.05% of the issued share capital.
In addition, the Company has been notified that Sylvie Dugat, a person closely associated (“PCA”) to Jean-Pierre Crinelli, has purchased 5,800 ordinary shares in the Company at a price of €2.58 per share.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Jean-Pierre Crinelli, Non-Executive Director
|
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
See 1(a) – classified as a PDMR of the Company
|
||||
|
b) |
Initial notification/ Amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Novacyt S.A. |
||||
|
b) |
LEI |
213800BWAC2BF295EG28 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
ordinary shares of €1/15 each
|
||||
|
|
Identification code |
FR0010397232 |
||||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
|
||||
|
e) |
Date of the transaction |
18 March 2022 |
||||
|
f) |
Place of the transaction |
Euronext |
||||
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Sylvie Dugat
|
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
PCA to Jean-Pierre Crinelli (PDMR)
|
||||
|
b) |
Initial notification/ Amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Novacyt S.A. |
||||
|
b) |
LEI |
213800BWAC2BF295EG28 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
ordinary shares of €1/15 each
|
||||
|
|
Identification code |
FR0010397232 |
||||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
|
||||
|
e) |
Date of the transaction |
15 March 2022 |
||||
|
f) |
Place of the transaction |
Euronext |
||||
– End –
Contacts
Novacyt SA
David Allmond, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
[email protected]/ [email protected]
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
[email protected] / [email protected] / [email protected]
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information, please refer to the website: www.novacyt.com
END
DSHSFFFWAEESEID
